All solid tumours require a vascular supply in order to progress. Although the ability to
induce angiogenesis (new blood vessel growth) has long been regarded as essential to this …

Single agent checkpoint inhibitor therapy has not been effective for most gastrointestinal
solid tumors, but combination therapy with drugs targeting additional immunosuppressive …

Intra-tumoral heterogeneity is a hallmark of glioblastoma that challenges treatment efficacy.
However, the mechanisms that set up tumor heterogeneity and tumor cell migration remain …

Vessel co-option is the movement of cancer cells towards and along the pre-existing
vasculature and is an alternative to angiogenesis to gain access to nutrients. Vessel co …

Abstract Background Glioma initiating cells (GICs), also known as glioma stem cells (GSCs),
play an important role in the progression and recurrence of glioblastoma multiforme (GBM) …

Glioblastoma (GBM) is the most common and malignant primary brain cancer in adults.
Without treatment the mean patient survival is approximately 6 months, which can be …

Vessel co-option is a non-angiogenic mechanism of tumour vascularisation in which cancer
cells utilise pre-existing blood vessels instead of inducing new blood vessel formation …

Cancer immunotherapy has been established as standard of care in different tumor entities.
After the first reports on synergistic effects with radiotherapy and the induction of abscopal …

Abstract AMD3100 (plerixafor), a CXCR4 antagonist, has opened a variety of avenues for
potential therapeutic approaches in different refractory diseases. The CXCL12/CXCR4 axis …

Glioblastoma, a subset of aggressive brain tumors, deploy several means to increase blood
vessel supply dedicated to the tumor mass. This includes typical program borrowed from …